Patents by Inventor Phillip Patrick Sharp
Phillip Patrick Sharp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12679848Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: GrantFiled: November 18, 2021Date of Patent: July 14, 2026Assignee: Merck Sharp & Dohme LLCInventors: Jianming Bao, Natalija Cernaka, Alan C. Cheng, Ying-Duo Gao, Salman Jabri, Jovan Alexander Lopez, Rohan Merchant, Anthony Ken Ogawa, Skylar K. Osler, Christopher J. Sinz, Phillip Patrick Sharp, Haiqun Tang, Maoqun Tian, Dong Xiao, Song Yang
-
Patent number: 12528786Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: GrantFiled: July 6, 2021Date of Patent: January 20, 2026Assignee: Merck Sharp & Dohme LLCInventors: Jacqueline D. Hicks, Rongze Kuang, Christopher J. Sinz, Matthew J. Lombardo, Jovan Alexander Lopez, Rohan Rajiv Merchant, Phillip Patrick Sharp, Zhicai Wu, Zhiqiang Zhao, Alan C. Cheng, Song Yang, Jianming Bao, Maoqun Tian, Galen Paul Shearn-Nance
-
Publication number: 20250099478Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: January 23, 2023Publication date: March 27, 2025Applicant: Merck Sharp & Dohme LLCInventors: Anthony K. Ogawa, Christopher J. Sinz, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Rohan Rajiv Merchant, Natalija Cernaka, Phillip Patrick Sharp, Jovan Alexander Lopez, Dong Xiao, Haiqun Tang, Maoqun Tian, Mihir B. Mandal, Jiafang He
-
Publication number: 20240245675Abstract: The present invention features compounds useful in the inhibition of the secretion of proteins. The compounds of the invention can be used in methods for treating diseases associated with protein secretion, and in methods for inhibiting protein secretion.Type: ApplicationFiled: January 29, 2024Publication date: July 25, 2024Inventors: Jordi MATA-FINK, Phillip Patrick SHARP, Raman TALWAR
-
Publication number: 20240190892Abstract: The present invention provides a compound of formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: March 16, 2022Publication date: June 13, 2024Applicant: Merck Sharp & Dohme LLCInventors: Natalija Cernaka, Anthony K. Ogawa, Alan C. Cheng, Jianming Bao, Phillip Patrick Sharp, Jovan Alexander Lopez, Dong Xiao, Haiqun Tang
-
Publication number: 20240025917Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: November 18, 2021Publication date: January 25, 2024Applicant: Merck Sharp & Dohme LLCInventors: Jianming Bao, Natalija Cernaka, Alan C. Cheng, Ying-Duo Gao, Salman Jabri, Jovan Alexander Lopez, Rohan Merchant, Anthony Ken Ogawa, Skylar K. Osler, Christopher J. Sinz, Phillip Patrick Sharp, Haiqun Tang, Maoqun Tian, Dong Xiao, Song Yang
-
Publication number: 20230348428Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: July 6, 2021Publication date: November 2, 2023Applicant: Merck Sharp & Dohme LLCInventors: Jacqueline D. HICKS, Rongze Kuang, Christopher J. Sinz, Matthew J. Lombardo, Jovan Alexander Lopez, Rohan Rajiv Merchant, Phillip Patrick Sharp, Zhicai Wu, Zhiqiang Zhao, Alan C. Cheng, Song Yang, Jianming Bao, Maoqun Tian, Galen Paul Shearn-Nance
-
Patent number: 11339193Abstract: Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.Type: GrantFiled: March 29, 2019Date of Patent: May 24, 2022Assignees: KEZAR LIFE SCIENCES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Dustin McMinn, John William Taunton, Phillip Patrick Sharp
-
Publication number: 20210017233Abstract: Provided herein are compounds that inhibit protein secretion, e.g., via inhibition of Sec61. Also provided are compositions of the inhibitor compounds, and methods of using these inhibitors. The compounds disclosed herein can be used, e.g., for the treatment of cancer, arthritis, and/or inflammation.Type: ApplicationFiled: March 29, 2019Publication date: January 21, 2021Inventors: Dustin McMinn, John William Taunton, Phillip Patrick Sharp
-
Patent number: 10167292Abstract: The present invention provides novel benzodiazepine derivatives of Formula I or pharmaceutically acceptable derivatives, polymorphs, salts or prodrugs thereof. Said compounds have potential as bromodomain (BRD) inhibitors.Type: GrantFiled: August 4, 2016Date of Patent: January 1, 2019Assignee: Catalyst Therapeutics Pty Ltd.Inventors: Chris Burns, Jean-Marc Garnier, Phillip Patrick Sharp, John Feutrill, Anthony Cuzzupe
-
Publication number: 20180230153Abstract: The present invention provides novel benzodiazepine derivatives of Formula I or pharmaceutically acceptable derivatives, polymorphs, salts or prodrugs thereof. Said compounds have potential as bromodomain (BRD) inhibitors.Type: ApplicationFiled: August 4, 2016Publication date: August 16, 2018Inventors: Chris Burns, Jean-Marc Garnier, Phillip Patrick Sharp, John Feutrill, Anthony Cuzzupe
